Pricing Log in Create free account
Saturday 17 October 2026 Export ANIX’s income statement to Excel — free account

ANIXA BIOSCIENCES INC

ANIX Healthcare Biotechnology

ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.67 0.11 −3.96%
Market cap
$96.7M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
n/a
Altman Z
14.47
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.46
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — 1 — — — — 2 8 — 7 —
Sell — — — — — — — — — — — —
Insider Ownership 4.01%

Capital & Financial Ratios $m

Market Cap 96.65
Revenue 0.97
Net Income (10.47)
Free Cash Flow (7.38)
Net Debt (13.86)
Current Ratio 8.55 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.00) (negative: loss-making)
P/S ratio 93.90 (above 10: high)
P/B ratio 6.91 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 8.82%
Next Y EPS Growth 0.00%
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth 3.03%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 83.5×, against a ten-year median of 77.5×; over the ten years it ranged from 1.6× in 2016 to 189× in 2022.
P/S against its own 10 years 49.47%
10-year low 10-year high
P/B against its own 10 years 52.55%
10-year low 10-year high
EV/Sales against its own 10 years 59.57%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 24 20 15 14
Receivables 0 0 — —
Inventory — — — —
Other — — — —
25 21 16 15
2023 2024 2025 Q'26
Payables 0 1 0 0
ST’ Debt — — — —
Other — — — —
2 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales (3.48%) (6.89%) (42.64%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 10.69% 11.04% (20.91%)

Revenue $m

Jan Apr Jul Oct Year
’26 — — — — —
’23 — 0 — — 0
’21 1 — — 0 1
’19 — 0 — — 0
’18 — 1 0 0 1
’17 — — 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jan Apr Jul Oct Year
’26 (3) (2) (2) — —
’25 (3) (2) (2) (1) (7)
’24 (2) (1) (3) (1) (7)
’23 (2) (1) (1) (2) (6)
’22 (1) (2) (1) (2) (6)
’21 (1) (1) (1) (1) (5)
’20 (2) (2) (1) (1) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jan Apr Jul Oct Year
’26 (3) (2) (2) — —
’25 (3) (2) (2) (1) (7)
’24 (2) (1) (3) (1) (7)
’23 (2) (1) (1) (2) (6)
’22 (1) (2) (1) (2) (6)
’21 (1) (1) (1) (1) (5)
’20 (2) (2) (1) (1) (6)
Fiscal quarters ending in the months shown.

EPS $

Jan Apr Jul Oct Year
’26 (0.08) (0.07) (0.08) — —
’25 (0.10) (0.09) (0.07) (0.09) (0.34)
’24 (0.10) (0.10) (0.10) (0.09) (0.39)
’23 (0.08) (0.07) (0.08) (0.09) (0.32)
’22 (0.13) (0.12) (0.09) (0.12) (0.45)
’21 (0.09) (0.08) (0.14) (0.13) (0.45)
’20 (0.13) (0.12) (0.11) (0.09) (0.45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to October

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 1.88 0.60 2.28 2.78 1.33 2.77 2.30 2.75 2.15 2.07

Analyst estimates 2026–2028

Powerpack
High 6.82 5.50 6.86 5.70 5.40 8.09 6.25 6.45 5.13 5.46
People
People Employees 7 7 8 8 4 5 5 5 5 4
Revenue/emp, $m 0.04 0.05 0.14 0.03 0.00 0.10 0.00 0.04 0.00 0.00
Income, $m
Income, $m Revenue 0 0 1 0 — 1 — 0 — —
Gross margin, % 100.00 100.00 100.00 100.00 0.00 100.00 0.00 100.00 — —
EBT (5) (5) (14) (12) (10) (13) (14) (10) (13) (11)
EBT margin, % (1,672.13) (1,381.79) (1,280.28) (4,727.48) 0.00 (2,564.06) 0.00 (4,728.57) 0.00 0.00
Net income (5) (5) (14) (12) (10) (13) (14) (10) (13) (11)
Depreciation 1 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.03 0.03 0.06 0.01 0.00 0.02 0.00 0.01 0.00 0.00
Earnings (0.57) (0.40) (0.79) (0.59) (0.45) (0.45) (0.45) (0.32) (0.39) (0.34)
Cash flow (0.39) (0.31) (0.24) (0.24) (0.28) (0.17) (0.21) (0.20) (0.23) (0.22)
Capex (0.02) 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (0.40) (0.31) (0.24) (0.25) (0.28) (0.17) (0.21) (0.20) (0.23) (0.22)
Book value 0.11 0.65 0.29 0.24 0.37 1.22 0.93 0.75 0.59 0.43
Shares, m 9 12 18 20 22 29 30 31 32 32
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 — 0.00 — —
P/S 132.13 33.01 48.39 56.21 — 190.90 — 100.72 — —
P/B 57.00 3.16 13.77 15.91 — 4.18 — 4.19 — —
EV/Sales 130.19 28.94 47.51 54.68 — 148.95 — 80.05 — —
EV/FCF (15.50) (5.80) (16.25) (15.13) — (23.15) — (12.60) — —
Cash, $m
Cash, $m Operating cash flow (3) (4) (4) (5) (6) (5) (6) (6) (7) (7)
Capex 0 0 0 0 0 0 — — — —
Free cash flow (4) (4) (4) (5) (6) (5) (6) (6) (7) (7)
Balance, $m
Balance, $m Working capital 3 6 4 5 8 35 28 23 19 14
Total debt 4 — — — 0 0 0 — — —
Net debt (3) (7) (5) (6) (9) (36) (30) (24) (20) (15)
Shareholders’ equity 1 8 5 5 8 35 28 23 19 14
Returns, %
Returns, % ROA (67.05) (97.20) (183.42) (182.81) (127.24) (56.68) (40.78) (35.08) (53.29) (58.01)
ROIC 0.00 (350.46) (7,004.46) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (166.85) (157.77) (213.58) (233.04) (153.22) (60.21) (43.18) (38.05) (59.41) (66.55)
Negative figures in brackets.

All 10 years →

Fiscal years to Oct 2023 · latest quarter Apr 2023

Charts ten years each

ANIXA BIOSCIENCES INC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MIST Milestone Pharmaceuticals Inc. $98.9M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
CBUS Cibus, Inc. $98.6M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%) Compare
PMVP PMV Pharmaceuticals, Inc. $97.4M — (loss-making) — — n/m +20.27% (above 0%: growing) 0.00% 0.00% Compare
NRXS Neuraxis, Inc. $97.2M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
IMUX Immunic, Inc. $96.9M — (loss-making) — — n/m −26.79% (below 0%: shrinking) 0.00% 0.00% Compare
ATRA Atara Biotherapeutics, Inc. $96.9M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%) Compare
ANIX ANIXA BIOSCIENCES INC $96.7M — (loss-making) — (loss-making) 0.00% n/m −17.14% (below 0%: shrinking) 0.00% 0.00%
ICCC ImmuCell Corporation $95.9M 126× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93% Compare
RANI Rani Therapeutics Holdings, Inc. $94.8M — (loss-making) — (loss-making) 0.00% n/m −55.29% (below 0%: shrinking) 100.00% (516.86%) Compare
Median of peers $97.0M — — +3.27% — +25.02% 77.77% (313.51%)

All 614 Biotechnology stocks →

ANIXA BIOSCIENCES INC (ANIX) key facts

  • ANIXA BIOSCIENCES INC (ANIX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00.
  • As of October 16, 2026, ANIX traded at $2.67, a market capitalization of $96.7 million.
  • Return on equity was −66.6% and debt-to-equity 0.00.
  • Its Altman Z-score is 14.47 (safe zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

ANIXA BIOSCIENCES INC (ANIX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ANIX · Data as of Apr 30, 2023 · For information only; not investment advice. · © 2026 stockrow.com